Transgene: Annual Results 2015 (Transgene) - Mar 13, 2016 - Anticipated initiation of P1/2 trial in combination with nivolumab in second-line stage IV NSCLC in US in H2 2016; Anticipated initiation of P1/2 trial in combination with an ICI and chemotherapy in first-line stage IV NSCLC in Europe in H2 2016; Anticipated initiation of P1/2 trial in early stage NSCLC (neo-adjuvant setting) in Europe in H2 2016
Anticipated new P1/2 trial • Non Small Cell Lung Cancer • Oncology
|